- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06388642
Pharmacokinetics of Afamelanotide in EPP Patients
April 24, 2024 updated by: Clinuvel Europe Limited
A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients With Erythropoietic Protoporphyria (EPP)
The purpose of this study is to evaluate the concentration of afamelanotide in serum after the administration of afamelanotide in adolescent and adult EPP patients.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
28
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Head of Clinical Operations
- Phone Number: +441372860765
- Email: mail@clinuvel.com
Study Locations
-
-
-
Rotterdam, Netherlands
- Recruiting
- Erasmus Medical Center
-
Contact:
- Erasmus Medical Centre
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- EPP patients aged between 12 and 70 years
- BMI between 15 and 30 kg/m2
- >50 kg
Exclusion Criteria:
- Any personal or direct family history of melanoma
- Any significant history of allergy and/or sensitivity to any of the contents of study drug product or lignocaine or other local anaesthetics if used
- Any significant illness during the four weeks before the study screening period
- Any evidence of hepatic or renal impairment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Afamelanotide 16 mg implant
|
afamelanotide 16mg implant will be administered to each patient during the study.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax (maximum Plasma Concentration)
Time Frame: Baseline to Day 7
|
Blood samples will be collected for analysis of afamelanotide plasma concentrations and understand what the maximum concentration in plasma is.
|
Baseline to Day 7
|
AUC(0-t) (area under the curve from administration to last observed concentration at time t)
Time Frame: Baseline to Day 7
|
Blood samples will be collected for analysis of afamelanotide plasma concentrations.
|
Baseline to Day 7
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
AUC(0-∞) (area under the curve extrapolated to infinite time)
Time Frame: Baseline to Day 7
|
Baseline to Day 7
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 7, 2024
Primary Completion (Estimated)
July 1, 2024
Study Completion (Estimated)
October 1, 2024
Study Registration Dates
First Submitted
April 4, 2024
First Submitted That Met QC Criteria
April 24, 2024
First Posted (Actual)
April 29, 2024
Study Record Updates
Last Update Posted (Actual)
April 29, 2024
Last Update Submitted That Met QC Criteria
April 24, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CUV052
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erythropoietic Protoporphyria
-
University of UtahNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); University... and other collaboratorsTerminatedErythropoietic Protoporphyria (EPP) | X Linked Erythropoietic ProtoporphyriaUnited States
-
Mitsubishi Tanabe Pharma America Inc.CompletedErythropoietic Protoporphyria (EPP)United States
-
University of Alabama at BirminghamPorphyria Rare Disease Clinical Research ConsortiumCompletedErythropoietic Protoporphyria (EPP)United States
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Rare... and other collaboratorsCompletedErythropoietic Protoporphyria | EPP | XLP | X-Linked Protoporphyria | XLPP | X-Linked Dominant Erythropoietic Protoporphyria | XLEPP | XLDPUnited States
-
Brigham and Women's HospitalCompleted
-
Amy K. Dickey, M.D.Wake Forest University Health Sciences; University of TexasRecruitingErythropoietic Protoporphyria | X-linked ProtoporphyriaUnited States
-
Icahn School of Medicine at Mount SinaiNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedErythropoietic Protoporphyria | EPP | X-linked Protoporphyria | XLPUnited States
-
Disc Medicine, IncActive, not recruitingErythropoietic ProtoporphyriaUnited States
-
Clinuvel Pharmaceuticals LimitedCompletedErythropoietic ProtoporphyriaNetherlands, Finland, France, Germany, Ireland, United Kingdom
-
Clinuvel Pharmaceuticals LimitedCompletedErythropoietic Protoporphyria
Clinical Trials on Afamelanotide 16mg implant
-
Clinuvel Pharmaceuticals LimitedCompleted
-
Clinuvel Pharmaceuticals LimitedCompletedPolymorphic Light Eruption (PLE)Austria, Australia, United Kingdom
-
Clinuvel (UK) Ltd.CompletedStudy to Evaluate the Safety and Efficacy of Afamelanotide in Patients With Variegate Porphyria (VP)Variegate PorphyriaNetherlands
-
Clinuvel Pharmaceuticals LimitedCompleted
-
Clinuvel Pharmaceuticals LimitedUnknownCarcinoma, Squamous Cell | Actinic Keratoses | Organ Transplant RecipientsAustralia, Sweden, Switzerland, Italy, France, Belgium, Germany
-
Tianjin Chasesun Pharmaceutical Co., LTDSouthwest Hospital, ChinaRecruiting
-
Clinuvel, Inc.Recruiting
-
Clinuvel Pharmaceuticals LimitedCompletedPolymorphic Light Eruption
-
Clinuvel Europe LimitedRecruitingXeroderma PigmentosumGermany
-
Clinuvel Pharmaceuticals LimitedCompletedAcne Vulgaris